Skip to main content

Associated with Estrogens

(See WARNINGS regarding induction of neoplasia, adverse effects on the fetus, increased incidence of gallbladder disease, and adverse effects similar to those of oral contraceptives, including thromboembolism). The following additional adverse reactions have been reported with estrogenic therapy, including oral contraceptives:

Genitourinary system

Breakthrough bleeding, spotting, change in menstrual flow.
Dysmenorrhea.
Premenstrual-like syndrome.
Amenorrhea during and after treatment.
Increase in size of uterine fibromyomata.
Vaginal candidiasis.
Change in cervical erosion and in degree of cervical secretion.
Cystitis-like syndrome.

Breasts

Tenderness, enlargement, secretion.

Gastrointestinal

Nausea, vomiting.
Abdominal cramps, bloating.
Cholestatic jaundice.

Skin

Chloasma or melasma which may persist when drug is discontinued.
Erythema multiforme.
Erythema nodosum.
Hemorrhagic eruption.
Loss of scalp hair.
Hirsutism.

Eyes

Steepening of corneal curvature.
Intolerance to contact lenses.

CNS

Headache, migraine, dizziness.
Mental depression.
Chorea.

Miscellaneous

Increase or decrease in weight.
Reduced carbohydrate tolerance.
Aggravation of porphyria.
Edema.
Changes in libido.

Associated with Methyltestosterone

Endocrine And Urogenital
  1. Female: The most common side effects of androgen therapy are amenorrhea and other menstrual irregularities, inhibition of gonadotropin secretion, and virilization, including deepening of the voice and clitoral enlargement. The latter usually is not reversible after androgens are discontinued. When administered to a pregnant woman androgens cause virilization of external genitalia of the female fetus.
  2. Skin and Appendages: Hirsutism, male pattern of baldness, and acne.
  3. Fluid and Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
  4. Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function test, rarely hepatocellular neoplasms, and peliosis hepatis (see WARNINGS).
  5. Hematologic: Suppression of clotting factors, II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.
  6. Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
  7. Metabolic: Increased serum cholesterol.
  8. Miscellaneous: Inflammation and pain at site of intramuscular injection or subcutaneous implantation of testosterone containing pellets, stomatitis with buccal preparations, and rarely anaphylactoid reactions.